CrossBridge Bio secures $10 million financing to advance the development of next-generation dual-payload ADC therapies

CAR-T Digest - August 2020

04 Nov 2024: CrossBridge Bio secures $10 million financing to advance the development of next-generation dual-payload ADC therapies

CrossBridge Bio has raised $10 million in a seed financing round, led by TMC Venture Fund and CE-Ventures, with additional participation from other investors
The company is developing dual-payload ADCs combining established and novel antibodies with various payload mechanisms to improve cancer treatment efficacy and safety
The funding will support the development of CBB-120, a dual-payload ADC targeting TROP-2 for solid tumors, and expand the company’s ADC pipeline
Capital will also be used to advance CrossBridge’s proprietary linker technology, which ensures targeted release of drug payloads in cancer cells to enhance treatment safety and effectiveness